Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Gainers
- Immutep Limited (NASDAQ:IMMP) rose 99.5% to $4.29 in pre-market trading after the company reported statistically significant survival benefit for key patient groups in the ongoing Phase IIb AIPAC study in metastatic breast cancer.
- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares rose 99.5% to $12.75 in pre-market trading after climbing 73% on Wednesday. SELLAS Life Sciences and 3D Medicines recently reported an Exclusive license agreement for development and commercialization of galinpepimut-S (GPS) and GPS+ in Greater China.
- UTStarcom Holdings Corp. (NASDAQ:UTSI) rose 94.7% to $2.59 in pre-market trading after climbing around 18% on Wednesday.
- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares rose 40.1% to $80.00 in pre-market trading. Greenwich LifeSciences shares jumped 998% on Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.
- Panbela Therapeutics Inc. (NASDAQ:PBLA) rose 39.8% to $5.99 in pre-market trading after jumping 24% on Wednesday. The company recently reported completion of enrollment in Phase 1b trial investigating SBP-101 combo therapy for first line metastatic pancreatic cancer.
- Veru Inc. (NASDAQ:VERU) rose 31.4% to $5.11 in pre-market trading. Veru shares climbed around 20% on Wednesday after the company posted upbeat quarterly sales and expanded oncology drug pipeline.
- Neos Therapeutics, Inc. (NASDAQ:NEOS) rose 28.4% to $0.71 in pre-market trading. Aytu BioScience and Neos Therapeutics reported a merger agreement.
- Silver Spike Acquisition Corp. (NASDAQ:SSPK) rose 23% to $12.90 in pre-market trading.
- Regulus Therapeutics Inc. (NASDAQ:RGLS) rose 17.1% to $1.05 in pre-market trading. Regulus Therapeutics recently announced the closing of a $19.4 million private placement.
- JanOne Inc. (NYSE:JAN) rose 16% to $4.80 in pre-market trading after declining over 4% on Wednesday.
- Asana, Inc. (NYSE:ASAN) shares rose 15% to $32.50 in pre-market trading after the company reported upbeat Q3 results and issued strong sales guidance. Piper Sandler raised the price target on the stock from $33 to $40.
- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) rose 12.2% to $1.75 in pre-market trading.
- Teligent, Inc. (NASDAQ:TLGT) rose 11.7% to $0.81 in pre-market trading after gaining 10% on Wednesday.
- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) rose 11.5% to $4.35 in pre-market trading after gaining 8% on Wednesday. Qualigen Therapeutics recently appointed Board member Amy Broidrick as EVP, Chief Strategy Officer and also names Sidney Emery, Jr. to its Board.
- Hoth Therapeutics, Inc. (NASDAQ:HOTH) rose 11.5% to $1.84 in pre-market trading.
- 17 Education & Technology Group Inc. (NASDAQ:YQ) rose 11.2% to $22.45 in pre-market trading following a 34% surge in the previous session. 17 Education & Technology Group, on Friday, priced its 27.4 million ADS at $10.50 per ADS.
- BiomX Inc. (NYSE:PHGE) rose 11.2% to $6.65 in pre-market trading as the company announced presentation of preclinical results of analysis of patient samples and engineering of phage for therapeutic applications in colorectal cancer.
- Progenity, Inc. (NASDAQ:PROG) rose 10.1% to $3.82 in pre-market trading.
- Editas Medicine, Inc. (NASDAQ:EDIT) rose 9.5% to $55.38 in pre-market trading after the company reported submission of investigational new drug application for EDIT-301 for sickle cell.
- Celsion Corporation (NASDAQ:CLSN) rose 9% to $0.77 in pre-market trading after surging over 12% on Wednesday.
- InflaRx N.V. (NASDAQ:IFRX) rose 8.8% to $5.22 in pre-market trading.
- 111, Inc. (NASDAQ:YI) rose 8.4% to $7.00 in pre-market trading.
- ObsEva SA (NASDAQ:OBSV) rose 8.1% to $2.26 in pre-market trading after the company reported additional Phase 3 PRIMROSE 1 and 2 study results confirming sustained efficacy and continued safety of linzagolix in the treatment of uterine fibroids.
- Landcadia Holdings II, Inc. (NASDAQ:LCA) rose 7% to $24.56 in pre-market trading after declining 7% on Wednesday.
- C3.ai, Inc. (NYSE:AI) shares rose 6.8% to $98.78 in pre-market trading. C3.ai shares climbed 120% on Wednesday after the company priced its 15.5 million share IPO at $42 per share.
- Kaixin Auto Holdings (NASDAQ:KXIN) shares rose 6% to $4.23 in pre-market trading after declining over 9% on Wednesday.
- Starbucks Corporation (NASDAQ:SBUX) rose 4.1% to $104.49 in pre-market trading after the company reaffirmed its guidance for FY21 at an investor event. The company also said it expects FY23 and FY24 adjusted EPS growth of 10% to 12% year over year. Starbucks also announced plans to launch a shaken iced espresso and oat milk this spring in its stores in the US.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and losers
Losers
- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) fell 24% to $4.79 in pre-market trading after climbing 24% on Wednesday. Oncternal Therapeutics, earlier during the week, announced updated interim clinical data from the ongoing Phase 1/2 CIRLL clinical trial.
- GeoVax Labs, Inc. (NASDAQ:GOVX) fell 18.9% to $4.65 in pre-market trading after surging 79% on Wednesday.
- Obalon Therapeutics, Inc. (NASDAQ:OBLN) fell 14.8% to $1.41 in pre-market trading after declining 16% on Wednesday.
- Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares fell 12.6% to $2.77 in pre-market trading. Xenetic Biosciences shares jumped 193% on Wednesday after the company's partner PJSC Pharmsynthez announced data from its Phase 3 study of PolyXen in chronic kidney disease.
- AquaBounty Technologies, Inc. (NASDAQ:AQB) shares fell 12% to $7.63 in pre-market trading after the company announced a common stock offering.
- Intec Pharma Ltd (NASDAQ:NTEC) fell 11.6% to $4.10 in pre-market trading. Intec Pharma shares jumped 34% on Wednesday after the company announced a cannabinoid research collaboration with GW Pharma.
- ZW Data Action Technologies Inc. (NASDAQ:CNET) fell 11.3% to $1.80 in pre-market trading. ZW Data Action Technologies shares jumped 39% on Wednesday after the company announced the opening of its first live streaming platform in Guangzhou, China.
- Francesca's Holdings Corporation (NASDAQ:FRAN) fell 11% to $2.50 in pre-market trading. Francescas shares jumped 23% on Wednesday after the company obtained interim approval to access $15 million of debtor-in-possession financing to facilitate its sale process.
- Genetic Technologies Limited (NASDAQ:GENE) fell 9.2% to $4.06 in pre-market trading after surging over 31% on Wednesday. Genetic Technologies, last week, entered into a three-year partnership with Taliaz for distribution rights to PREDICTIX products in US, New Zealand and Australia.
- Naked Brand Group Limited (NASDAQ:NAKD) fell 8.9% to $0.1585 in pre-market trading after declining around 7% on Wednesday.
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares fell 8.3% to $2.66 in pre-market trading. Citigroup, on Tuesday, upgraded the stock from Neutral to Buy and raised its price target from $2.1 to $6 per share.
- Recon Technology, Ltd. (NASDAQ:RCON) fell 8% to $1.62 in pre-market trading after surging 24% on Wednesday.
- Aptorum Group Limited (NYSE:APM) shares fell 7.8% to $2.50 in pre-market trading after declining around 5% on Wednesday.
- Check-Cap Ltd. (NASDAQ:CHEK) shares fell 7.6% to $0.3511 in pre-market trading after gaining 7% on Wednesday.
- Qiwi plc. (NASDAQ:QIWI) fell 7% to $12.65 in pre-market trading.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.